GETTING MY TRASTUZUMAB BIOSIMILAR TO WORK

Among the most underneath-investigated “driving forces” involved with trastuzumab resistance is PTEN. Nagata et al. (2004) noted the lack of PTEN was observed in 36% of HER2-beneficial Principal breast tumor specimens from patients with phase IV sickness. Also, they also showed that clients with PTEN-deficient tumors had remarkably decrease Gen